Naltrexone

Active ingredient: Naltrexone

In short: Treatment with naltrexone for extended-release injectable suspension should be part of a comprehensive management program that includes psychosocial support. Naltrexone for extended-release injectable suspension is indicated for the treatment of alcohol dependence in patients who are able to abstain

Forms & strengthsNaltrexone for extended-release injectable suspension is an off-white to light tan powder for injectable suspension in a 5 mL single-dose vial. Naltrexone for extended-release injectable suspension contains 380 mg of naltrexone in a microsphere formulation …
LabelAmneal Pharmaceuticals NY LLC
Label updatedMay 20, 2026

What is Naltrexone used for?

Treatment with naltrexone for extended-release injectable suspension should be part of a comprehensive management program that includes psychosocial support.

Naltrexone for extended-release injectable suspension is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with naltrexone for extended-release injectable suspension. Patients should not be actively drinking at the time of initial naltrexone for extended-release injectable suspension administration.

Naltrexone for extended-release injectable suspension is indicated for the prevention of relapse to opioid dependence, following opioid detoxification.

Naltrexone dosage

Naltrexone for extended-release injectable suspension must be prepared and administered by a healthcare provider.

Naltrexone for extended-release injectable suspension must ONLY be administered as a deep intramuscular gluteal injection.

Parenteral products should be visually inspected for particulate matter and discoloration prior to administration whenever solution and container permit. A properly mixed suspension will be milky white, will not contain clumps, and will move freely down the wall of the vial .

Prior to initiating naltrexone for extended-release injectable suspension, an opioid-free duration of a minimum of 7–10 days is recommended for patients, to avoid precipitation of opioid withdrawal that may be severe enough to require hospitalization .

The recommended dose of naltrexone for extended-release injectable suspension is 380 mg delivered intramuscularly (deep) as a gluteal injection every 4 weeks or once a month, alternating buttocks for each subsequent injection, using the carton components provided . The needles provided in the carton are customized needles. Naltrexone for extended-release injectable suspension must not be injected using any other needle. The needle lengths (either 1 1/2 or 2 inches) may not be adequate in every patient because of body habitus. Body habitus should be assessed prior to each injection for each patient to assure that needle length is adequate for intramuscular administration. For patients with a larger amount of subcutaneous tissue overlying the gluteal muscle, the administering healthcare provider may utilize the supplied 2-inch needle with needle protection device to help ensure that the injectate reaches the intramuscular mass. For very lean patients, the 1 1/2-inch needle may be appropriate to prevent the needle contacting the periosteum. Either needle may be used for patients with average body habitus. Healthcare providers should ensure that the naltrexone for extended-release injectable suspension injection is given correctly, and should consider alternate treatment for those patients whose body habitus precludes an intramuscular gluteal injection with one of the provided needles.

If a patient misses a dose, he/she should be instructed to receive the next dose as soon as possible.

Pretreatment with oral naltrexone is not required before using naltrexone for extended-release injectable suspension.

At the initial naltrexone for extended-release injectable suspension injection and with each subsequent injection, inform patients and caregivers about opioid overdose reversal agents (e.g., naloxone, nalmefene) and discuss the importance of having access to an opioid overdose reversal agent. …

How to take Naltrexone — instructions & advice from the label

Advise the patient to read the FDA-Approved patient labeling (Medication Guide).

Physicians should include the following issues in discussions with patients for whom they prescribe naltrexone for extended-release injectable suspension.

Naltrexone for Extended-Release Injectable Suspension for Opioid Use Disorder:

Advise patients that if they previously used opioids, they may be more sensitive to lower doses of opioids and at risk of accidental overdose should they use opioids when their next dose is due, if they miss a dose, or after naltrexone for extended-release injectable suspension treatment is discontinued. It is important that patients inform family members and the people closest to the patient of this increased sensitivity to opioids and the risk of overdose. Educate patients and caregivers on how to recognize the signs and symptoms of an opioid overdose.

Advise patients that because naltrexone for extended-release injectable suspension can block the effects of opioids, patients will not perceive any effect if they attempt to self-administer heroin or any other opioid drug in small doses while on naltrexone for extended-release injectable suspension. …

Warnings & precautions

Do not take this medicine if: Naltrexone for extended-release injectable suspension is contraindicated in:

Patients receiving opioid analgesics .

Patients with current physiologic opioid dependence .

Patients in acute opioid withdrawal .

Any individual who has failed the naloxone challenge test or has a positive urine screen for opioids .

Patients who have previously exhibited hypersensitivity to naltrexone, PLG, carboxymethylcellulose, or any other components of the diluent .

After opioid detoxification, patients are likely to have reduced tolerance to opioids. Naltrexone for extended-release injectable suspension blocks the effects of exogenous opioids for approximately 28 days after administration. However, as the blockade wanes and eventually dissipates completely, patients who have been treated with naltrexone for extended-release injectable suspension may respond to lower doses of opioids than previously used, just as they would have shortly after completing detoxification. This could result in potentially life-threatening opioid intoxication (respiratory compromise or arrest, circulatory collapse, etc.) if the patient uses previously tolerated doses of opioids. Cases of opioid overdose with fatal outcomes have been reported in patients who used opioids at the end of a dosing interval, after missing a scheduled dose, or after discontinuing treatment.

Patients should be alerted that they may be more sensitive to opioids, even at lower doses, after naltrexone for extended-release injectable suspension treatment is discontinued, especially at the end of a dosing interval (i.e., near the end of the month that naltrexone for extended-release injectable suspension was administered), or after a dose of naltrexone for extended-release injectable suspension is missed. …

Naltrexone side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Accidental Opioid Overdose

Injection Site Reactions

Precipitated Opioid Withdrawal

Hepatotoxicity

Depression and Suicidality

Eosinophilic Pneumonia

Hypersensitivity Reactions

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In all controlled and uncontrolled trials during the premarketing development of naltrexone for extended-release injectable suspension, more than 1100 patients with alcohol and/or opioid dependence have been treated with naltrexone for extended-release injectable suspension. Approximately 700 patients have been treated for 6 months or more, and more than 400 for 1 year or longer.

Adverse Events Leading to Discontinuation of Treatment

Alcohol Dependence

In controlled trials of 6 months or less in alcohol-dependent patients, 9% of alcohol-dependent patients treated with naltrexone for extended-release injectable suspension discontinued treatment due to an adverse event, as compared to 7% of the alcohol-dependent patients treated with placebo. …

Drug interactions

Patients taking naltrexone for extended-release injectable suspension may not benefit from opioid-containing medicines. Naltrexone antagonizes the effects of opioid-containing medicines, such as cough and cold remedies, antidiarrheal preparations and opioid analgesics.

About this medicine

Naltrexone for extended-release injectable suspension is supplied as a microsphere formulation of naltrexone for suspension, to be administered by deep intramuscular injection by a healthcare practitioner. Naltrexone for extended-release injectable suspension contains naltrexone base anhydrous as the active pharmaceutical ingredient. Naltrexone is an opioid antagonist with little, if any, opioid agonist activity.

Naltrexone is morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-(5α) (CAS Registry # 16590-41-3). The molecular formula is C20H23NO4 and its molecular weight is 341.41 in the anhydrous form (ie, < 1% maximum water content). The structural formula is:

Naltrexone base anhydrous is an off-white to a light tan powder with a melting point of 168 °C to 170 °C (334 °F to 338 °F). It is insoluble in water and is soluble in ethanol. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 6de5637f-d527-4228-af1a-3aae71155cb5. Read the full official label on DailyMed.